Investor Relations

Press Releases

  • DATE
  • TITLE AND SUMMARY
  • VIEW
March 25, 2019

TEL AVIV, Israel , March 25, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), today announces that the Company will present data on its Phase 3 drug candidate VB-111, at the 2019 American Association for Cancer Research (AACR) Annual Meeting , to be held March 29 - April 3, 2019 at...

March 19, 2019

Data Presented at Society of Gynecologic Oncology (SGO) 50th Annual Meeting on Women's Cancer® TEL AVIV, Israel , March 19, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), today announced the presentation of human data indicating that the viral anti-cancer investigational therapy VB-111...

March 14, 2019

TEL AVIV, Israel , March 14, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio...

March 11, 2019

TEL AVIV, Israel , March 11, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announces that the company will present data on its Phase 3...

February 26, 2019

TEL AVIV, Israel, Feb. 26, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), (the “Company”) today announced new data implicating the potential of its VB-600 platform of antibodies targeting MOSPD2 (motile sperm domain-containing protein 2) for treatment of various inflammatory...

February 20, 2019

TEL AVIV, Israel , Feb. 20, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (the “Company”) today announced that it has been awarded a non-dilutive grant of over 10 million New Israeli Shekels (approximately $2.9 million ) by the Israel Innovation Authority (IIA) for 2019.  The funds will...

February 19, 2019

TEL AVIV, Israel , Feb. 19, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), today announces that the Company will present new data on the potential of its VB-600 platform targeting MOSPD2 for inflammatory and oncology indications, at the Keystone Symposia on Myeloid Cells, to be held...

November 21, 2018

TEL AVIV, Israel , Nov. 21, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announces it will provide a corporate update, in a Fireside Chat...

November 20, 2018

Conference Call and Webcast at 8:30am Eastern Time Today TEL AVIV, Israel , Nov. 20, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced financial results for the third quarter ended September 30, 2018 and provided a corporate update....

November 16, 2018

Additional Analyses Provide Insight into Treatment Effect of VB-111 TEL AVIV, Israel , Nov. 16, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), is reporting results today from its Phase 3 GLOBE study in patients with recurrent glioblastoma (rGBM) which was designed to evaluate VB-111 in...

View all press releases »